Onyx Adds Cancer Drug Maker Proteolix For $276M
Onyx Pharmaceuticals Inc., a biopharmaceutical company specializing in cancer treatments, announced Monday that it had agreed to purchase Proteolix Inc. for an initial cash payment of $276 million....To view the full article, register now.
Already a subscriber? Click here to view full article